Company intelligence / Profile preview
AATec Medical
Planegg-Martinsried, Bavaria, Germanyaatec-medical.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
AATec has robust preclinical safety and efficacy data for its lead candidate ATL‑105, an inhaled recombinant alpha‑1 antitrypsin therapy targeting neutrophilic airway inflammation. The company is preparing IND-enabling activities and expects to enter clinical trials by ~2026. The approach aims to maximize local therapeutic effect while minimizing systemic side effects.
- Therapeutic areas
- PulmonologyRare DiseasesInfectious Diseases
- Modalities
- Recombinant proteins (specifically recombinant alpha‑1 antitrypsin)Inhaled biologics/proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beurer – device development/manufacturing partnership for inhaled drug products/delivery devicesSPRIND – funding partner via Germany’s Federal Agency for Disruptive Innovation
Beyond the preview
Go deeper on AATec Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AATec Medical.